A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

Completed · Phase 2 · Has a placebo group

Conditions studied: Hallux Valgus

In brief

This is a Phase 2, randomized, double-blind, 2-part comparator- and placebo-controlled study to evaluate the safety, PK, and efficacy of TLC590 via a single infiltrative local administration in adult subjects following bunionectomy.

Key facts

Study ID

NCT03838133

Run by

Taiwan Liposome Company

People needed

150

Starts

2019-03-05

Expected to finish

2020-03-31

Last updated by the study team

2020-04-07

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able and willing to provide a written informed consent.
• Male or female between 18 and 65 years of age.
• Body mass index ≤ 35 kg/m2.
• Mild to moderate hallux valgus deformity.
• Scheduled to undergo a primary, unilateral first metatarsal bunionectomy repair under local anesthesia.
• American Society of Anesthesiology Physical Status Classification of 1 or 2 at screening.
• Female subjects are eligible only if all of the following apply:
• Not pregnant;
• Not lactating;
• Not planning to become pregnant during the study;
• Commits to the use of an acceptable form of birth control for the duration of the study and for 42 days from administration of study drug.
• Male subjects must be surgically sterile (biologically or surgically) or commit to the use of a reliable method of birth control, for the duration of the study until at least 1 week after the administration of study medication.

You may not qualify if…

• Clinically significant abnormal clinical laboratory test value.
• Evidence of a clinically significant 12-lead ECG abnormality.
• History or evidence of orthostatic hypotension, syncope or other syncopal attacks.
• History or clinical manifestations of significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other condition that would preclude participation in the study.
• A history of seizure disorder or currently taking anticonvulsants.
• History of hypersensitivity to ropivacaine, any other amide-type local anesthetic, propofol, lidocaine, midazolam, acetaminophen, naproxen, morphine or oxycodone (or other opioids).
• Concurrent painful physical condition that may confound post-operative pain assessments.
• Persistent or recurrent nausea and/or vomiting due to other etiologies.
• History of severe or refractory post-operative nausea or vomiting (PONV) deemed clinically significant.
• History of alcohol abuse or prescription/illicit drug abuse within 2 years.
• Current evidence of alcohol abuse within 6 months.
• Received opioid therapy for longer than 4 days per week within 2 months or opioid use within 2 weeks.
• Use of concurrent therapy that could interfere with the evaluation of efficacy or safety.
• Unable to discontinue medications that have not been at a stable dose for at least 14 days prior to the study surgical procedure, within 5 half-lives of the specific prior medication.
• Use of any of the following medications within 5 half-lives or as specified prior to the study surgical procedure:
• Low-dose aspirin therapy for cardiovascular protection
• Class III antiarrhythmic drugs
• Strong CYP1A2 inhibitors
• CYP1A2 substrates
• Strong CYP3A4 inhibitors
• Corticosteroids, either systemically, inhaled either intranasally or orally, or by intra-articular injection, or NSAIDs within 14 days
• Any investigational product within 30 days.
• Positive results on the urine drug screen or alcohol breath test indicative of illicit drug or alcohol abuse.
• History or positive test results for HIV; active Hepatitis B or C.
• Contralateral foot bunionectomy in the last 3 months or have collateral procedures.

Where it is running

• Arizona Research Center — Phoenix, Arizona, United States
• Anaheim Clinical Trials, LLC — Anaheim, California, United States
• Chesapeake Research Group — Pasadena, Maryland, United States
• Endeavor Clinical Trials — San Antonio, Texas, United States
• JBR clinical research — Draper, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.